Incidence of neuroepithelial Primary Brain Tumors (nPBT) varies, ranging from 7.3 to 11.6 cases/100,000/year across Europe. We present incidence and survival of nPBT in the Emilia-Romagna region (ER), Italy. This study is the largest in Southern Europe. Specialists in neurosurgery, neurology, neuroradiology, oncology, radiotherapy, genetics, and pathology of ER notified all suspected nPBT adult cases residing in ER (4,337,966 inhabitants) observed during 2009. Furthermore, through ICD-9 discharge codes, we identified and reviewed all possible cases. Neuroepithelial PBT diagnosis was based on histological or radiological findings. We included 400 incident nPBT cases, of which 102 (25%) were retrospectively identified. These latter were significantly older. The standardized incidence was 10.5/100,000/year (95% CI 9.4â11.5), higher for men. It was 9.2/100,000/year (95% CI 8.3â10.2) for astrocytic tumors, 0.6/100,000/year (95% CI 0.4â0.9) for oligodendroglial tumors, and 7.1 (95% CI 6.3â8.0) for glioblastoma (GBM). Among GBM patients, median survival was 249Â days if prospectively identified vs. 132Â days when identified through ICD-9 codes (pÂ
Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy
FAINARDI, EnricoMembro del Collaboration Group
;CAVALLO, Michele AlessandroMembro del Collaboration Group
;FALLICA, ELISAMembro del Collaboration Group
;GRANIERI, Enrico Gavino GiuseppeMembro del Collaboration Group
;LATINI, FrancescoMembro del Collaboration Group
;SCHIVALOCCHI, ROBERTAMembro del Collaboration Group
;TOLA, Maria RosariaMembro del Collaboration Group
;RAMPONI, VaniaMembro del Collaboration Group
;
2017
Abstract
Incidence of neuroepithelial Primary Brain Tumors (nPBT) varies, ranging from 7.3 to 11.6 cases/100,000/year across Europe. We present incidence and survival of nPBT in the Emilia-Romagna region (ER), Italy. This study is the largest in Southern Europe. Specialists in neurosurgery, neurology, neuroradiology, oncology, radiotherapy, genetics, and pathology of ER notified all suspected nPBT adult cases residing in ER (4,337,966 inhabitants) observed during 2009. Furthermore, through ICD-9 discharge codes, we identified and reviewed all possible cases. Neuroepithelial PBT diagnosis was based on histological or radiological findings. We included 400 incident nPBT cases, of which 102 (25%) were retrospectively identified. These latter were significantly older. The standardized incidence was 10.5/100,000/year (95% CI 9.4â11.5), higher for men. It was 9.2/100,000/year (95% CI 8.3â10.2) for astrocytic tumors, 0.6/100,000/year (95% CI 0.4â0.9) for oligodendroglial tumors, and 7.1 (95% CI 6.3â8.0) for glioblastoma (GBM). Among GBM patients, median survival was 249Â days if prospectively identified vs. 132Â days when identified through ICD-9 codes (pÂFile | Dimensione | Formato | |
---|---|---|---|
Baldin2017_Article_IncidenceOfNeuroepithelialPrim.pdf
solo gestori archivio
Descrizione: Full text editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
601.75 kB
Formato
Adobe PDF
|
601.75 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.